Study design
primary acquired nasolacrimal duct obstruction, epiphora
EPIPHORA
This is a single-center, double-blind, prospective, randomized, clinical study. The study was conducted in the Ophthalmology Department, Zagazig Faculty of Medicine during the period between March 2022 and September 2022 to treat patients with epiphora caused by primary acquired nasolacrimal duct obstruction with or without + ve regurge test.This research was approved by the Institutional Review Board of Zagazig University Faculty of Medicine (IRB#9231-27-3-2022) and was adherent to the ethical principles outlined in the Declaration of Helsinki as amended in 2013. Also, approval of this study design was obtained from the Pan African Clinical Trial Registry (ID number PACTR202206674510595). 